Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumorsDebashis Sarker, Udai Banerji, Rupert Dixon et al.|Cancer Research|2023Cited by 6